How have SPHDF shares performed in 2023?

Santhera Pharmaceuticals' stock was trading at $14.10 on January 1st, 2023. Since then, SPHDF shares have decreased by 5.3% and is now trading at $13.35. View the best growth stocks for 2023 here .

Are investors shorting Santhera Pharmaceuticals?

Santhera Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 136,400 shares, an increase of 69.0% from the October 15th total of 80,700 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 104.9 days. View Santhera Pharmaceuticals' Short Interest .

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Santhera Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:SPHDF)

$13.35

0.00 (0.00%)

(As of 11/28/2023 ET)

Compare

Today's Range: $13.35
▼
$13.35
50-Day Range: $0.68
▼
$13.35
52-Week Range: $9.40
▼
$13.35

Volume: N/A
Average Volume: 3,788 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

About Santhera Pharmaceuticals Stock (OTCMKTS:SPHDF)

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

SPHDF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SPHDF Stock News Headlines

October 27, 2023 | finance.yahoo.com

Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

October 26, 2023 | reuters.com

US FDA approves Santhera's Duschenne drug

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 13, 2023 | markets.businessinsider.com

Santhera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular Dystrophy

October 13, 2023 | markets.businessinsider.com

Positive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD Treatment

October 13, 2023 | finance.yahoo.com

Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

September 8, 2023 | seekingalpha.com

Santhera Pharmaceuticals reports 1H results

September 8, 2023 | finance.yahoo.com

Santhera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The Corner

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 7, 2023 | finance.yahoo.com

Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update

July 31, 2023 | benzinga.com

Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

July 31, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)

June 29, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Split

June 29, 2023 | finance.yahoo.com

Santhera Publishes Timeline of the Reverse Share Split

June 27, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meeting

June 27, 2023 | finance.yahoo.com

Shareholders Approve all Board Proposals at Today’s Annual General Meeting

June 21, 2023 | msn.com

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

June 20, 2023 | finance.yahoo.com

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

June 20, 2023 | markets.businessinsider.com

Santhera Grants North America License For Vamorolone To Catalyst Pharma

June 20, 2023 | finance.yahoo.com

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

June 6, 2023 | finance.yahoo.com

Santhera Publishes Agenda for its Annual General Meeting

June 2, 2023 | seekingalpha.com

Santhera Pharmaceuticals GAAP EPS of -CHF1.17

June 1, 2023 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022

May 31, 2023 | finance.yahoo.com

Santhera Publishes Annual Report 2022

May 24, 2023 | thestreet.com

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About

May 13, 2023 | thestreet.com

Santhera Drug Wins European Approval for Rare Blindness Disease

April 27, 2023 | finance.yahoo.com

Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update

See More Headlines

Receive SPHDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:SPHDF
CUSIP: N/A
CIK: N/A
Web: www.santhera.com
Phone: (161) 906-8950
Fax: N/A
Employees: 45
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Thomas Meier Ph.D. (Age 61)
Founder & Chairman
Comp: $94.62k
Mr. Dario Eklund (Age 55)
Chief Executive Officer
Comp: $920.58k
Mr. Andrew P. Smith CGMA (Age 60)
FCMA, Chief Financial Officer
Mr. Oliver Strub (Age 60)
Executive VP, General Counsel & Secretary
Mr. Günther Metz Ph.D. (Age 65)
Head of Business Development & Executive VP
Mr. Shabir Hasham M.D.
Chief Medical Officer
Ms. Stephanie Brown B.Sc. (Age 62)
M.B.A., President of North America
Mr. Marc Schrader
Head of Technical Development & Operations
Ms. Eva Kalias
Head of Investor Relations & Communications
Mr. Neville Kodkani M.D.
Head of Global Marketing & Partner Management

Key Competitors

View All Competitors

SPHDF Stock Analysis - Frequently Asked Questions

How have SPHDF shares performed in 2023?: Santhera Pharmaceuticals' stock was trading at $14.10 on January 1st, 2023. Since then, SPHDF shares have decreased by 5.3% and is now trading at $13.35.
View the best growth stocks for 2023 here.
Are investors shorting Santhera Pharmaceuticals?: Santhera Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 136,400 shares, an increase of 69.0% from the October 15th total of 80,700 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 104.9 days.
View Santhera Pharmaceuticals' Short Interest.
When did Santhera Pharmaceuticals' stock split?: Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
How do I buy shares of Santhera Pharmaceuticals?: Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SPHDF) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial